Desmoid Tumors Pipeline Status 2024: Clinical Trials Overview and Therapeutic Landscape by DelveInsight | AFT Pharma, Timber Pharma, SpringWorks Therapeutics, Iterion Therapeutics, Cellestia Biotech

The Desmoid Tumors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Desmoid Tumors Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Desmoid Tumors Market.

Some of the key takeaways from the Desmoid Tumors Pipeline Report:

• Companies across the globe are diligently working toward developing novel Desmoid Tumors treatment therapies with a considerable amount of success over the years. Desmoid Tumors Key players such as – SpringWorks Therapeutics, Ayala Therapeutics, Iterion Therapeutics, and others, are developing therapies for the Desmoid Tumors treatment 

• Desmoid Tumors Emerging therapies such as – Nirogacestat, AL102, Tegavivint, and others are expected to have a significant impact on the Desmoid Tumors market in the coming years. 

• In March 2024, Immunome, Inc. (Nasdaq: IMNM), a biotechnology firm dedicated to creating innovative targeted cancer therapies, announced the successful acquisition of AL102 and the related drug candidate AL101 from Ayala Pharmaceuticals, Inc.

• In November 2023, SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a biopharmaceutical company specializing in severe rare diseases and cancer, announced that the U.S. Food and Drug Administration (FDA) has approved OGSIVEO™ (nirogacestat), an oral gamma secretase inhibitor, for the treatment of adult patients with progressing desmoid tumors needing systemic therapy. Previously, the FDA had granted nirogacestat breakthrough therapy, fast track, and orphan drug designations for desmoid tumor treatment.  

Get a Free Sample PDF Report to know more about Desmoid Tumors Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/desmoid-tumors-pipeline-insight

Desmoid Tumors Overview

Desmoid tumors, also known as aggressive fibromatosis, are rare, non-metastatic but locally invasive tumors that arise from the connective tissue, which includes tendons and ligaments. Although they do not spread to distant organs, desmoid tumors can be very aggressive locally and can recur after surgical removal.

Route of Administration

Desmoid Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Desmoid Tumors Pipeline Therapeutics Assessment

• Desmoid Tumors Assessment by Product Type

• Desmoid Tumors By Stage and Product Type

• Desmoid Tumors Assessment by Route of Administration

• Desmoid Tumors By Stage and Route of Administration

• Desmoid Tumors Assessment by Molecule Type

• Desmoid Tumors by Stage and Molecule Type

DelveInsight’s Desmoid Tumors Report covers around 4+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Desmoid Tumors product details are provided in the report. Download the Desmoid Tumors pipeline report to learn more about the emerging Desmoid Tumors therapies

Some of the key companies in the Desmoid Tumors Therapeutics Market include:

Key companies developing therapies for Desmoid Tumors treatment are – SpringWorks Therapeutics, Iterion Therapeutics, Cellestia Biotech, BioSpecifics Technologies Corp., 180 Life Sciences, AFT Pharma, Timber Pharmaceuticals, MedPacto, Intas Pharmaceuticals, Jina pharmaceuticals, and others.

Emerging Desmoid Tumors Drugs Under Different Phases of Clinical Development Include:

• Nirogacestat: SpringWorks Therapeutics

• AL102: Ayala Therapeutics

• Tegavivint: Iterion Therapeutics

Desmoid Tumors Pipeline Analysis:

The Desmoid Tumors pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Desmoid Tumors with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Desmoid Tumors Treatment.

• Desmoid Tumors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Desmoid Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Desmoid Tumors market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Desmoid Tumors drugs and therapies

Desmoid Tumors Pipeline Market Drivers

• No licensed therapy for Desmoid Tumor, which presents an opportunity for pharmaceutical companies to enter the market

• Market growth of Desmoid Tumors will be boosted by increased R&D and the anticipated introduction of new therapies

Desmoid Tumors Pipeline Market Barriers

• There are challenges in conducting rare cancer clinical trials due to issues surrounding clinical trial design, patient recruitment, and analysis

• Lack of approved therapies poses a significant burden on Desmoid Tumors patients

• Owing of its rarity, Desmoid Tumors poses research obstacles, and only a few attempts have been made to develop medications for the condition

Scope of Desmoid Tumors Pipeline Drug Insight    

• Coverage: Global

• Key Desmoid Tumors Companies: SpringWorks Therapeutics, Ayala Therapeutics, Iterion Therapeutics, and others

• Key Desmoid Tumors Therapies: Nirogacestat, AL102, Tegavivint, and others

• Desmoid Tumors Therapeutic Assessment: Desmoid Tumors current marketed and Desmoid Tumors emerging therapies

• Desmoid Tumors Market Dynamics: Desmoid Tumors market drivers and Desmoid Tumors market barriers 

Request for Sample PDF Report for Desmoid Tumors Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/